# Argentina Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Argentina HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Argentina (ARG)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $1.7B
- Products: 37
- Buyer markets: 25
- Average CAGR: +14.2%
- Global sector size: $773.7B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $310.3B | $139.6M | $116.5B | +7.3% | 22 | +0.1% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $165.1B | $6.8M | $67.1B | +19.7% | 16 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $20.1B | $633.4M | $33.8B | +11.2% | 4 | +2.3% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $24.2B | $37.5K | $30.9B | -25.5% | 4 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $24.6B | $103.5K | $20.8B | +3.4% | 5 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $15.9B | $33.6K | $19.8B | +28.1% | 2 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $590.2K | $16.8B | +8.4% | 3 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $4.7M | $16.1B | +12.1% | 7 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $76.5K | $15.9B | +10.6% | 8 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $29.3B | $2.7M | $15.9B | +13.4% | 6 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $335.1M | $11.7B | +31.9% | 5 | +2.2% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $4.3M | $10.7B | +6.8% | 3 | +0.1% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $5.5M | $8.5B | +3.6% | 3 | +0.1% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $16.8B | $2.2M | $7.0B | +89.4% | 3 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $6.9M | $6.3B | +15.1% | 3 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $43.5 | $4.8B | -24.1% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.0B | $968.4K | $4.4B | +21.2% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $258.8K | $4.1B | +4.6% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $1.6M | $3.8B | +38.0% | 2 | +0.1% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $3.1B | $780.1K | $2.9B | +14.0% | 2 | +0.0% |
| HS 283691 - Carbonates: lithium carbonate | $2.5B | $488.0M | $2.8B | +57.2% | 1 | +19.6% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $5.2M | $2.4B | +27.6% | 1 | +0.2% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $83.2 | $2.4B | +59.1% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.6M | $2.0B | +22.6% | 1 | +0.1% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $42.7K | $2.0B | -1.8% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $662.8K | $1.9B | +33.1% | 1 | +0.0% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $492.2 | $1.8B | -15.3% | 1 | +0.0% |
| HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $9.1M | $1.7B | -0.6% | 1 | +0.5% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $55.0 | $1.7B | +28.4% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $4.5M | $1.7B | +28.3% | 1 | +0.5% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $20.7 | $1.4B | -10.6% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $6.8K | $1.4B | +38.4% | 1 | +0.0% |
| HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $9.2K | $1.3B | +22.3% | 1 | +0.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $151.2K | $1.3B | +16.5% | 1 | +0.1% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $136.0K | $1.3B | -9.8% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $205.0K | $1.2B | -6.7% | 1 | +0.0% |
| HS 290250 - Cyclic hydrocarbons: styrene | $768.8M | $468.5K | $1.1B | +9.3% | 1 | +0.1% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $151.5B calculated opportunity across 21 products.
- Switzerland, Liechtenstein (CHE): $37.8B calculated opportunity across 5 products.
- Germany (DEU): $35.9B calculated opportunity across 11 products.
- Slovenia (SVN): $34.5B calculated opportunity across 4 products.
- China (CHN): $28.2B calculated opportunity across 10 products.
- Belgium (BEL): $23.8B calculated opportunity across 5 products.
- Netherlands (NLD): $19.1B calculated opportunity across 5 products.
- Italy (ITA): $13.4B calculated opportunity across 4 products.
- Mexico (MEX): $12.9B calculated opportunity across 7 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Spain (ESP): $11.6B calculated opportunity across 6 products.
- France (FRA): $10.5B calculated opportunity across 5 products.

## Growth stars

- HS 330499: +89.4% average CAGR, $7.0B calculated opportunity.
- HS 282590: +59.1% average CAGR, $2.4B calculated opportunity.
- HS 283691: +57.2% average CAGR, $2.8B calculated opportunity.
- HS 340220: +38.4% average CAGR, $1.4B calculated opportunity.
- HS 381512: +38.0% average CAGR, $3.8B calculated opportunity.
- HS 382319: +33.1% average CAGR, $1.9B calculated opportunity.
- HS 382600: +31.9% average CAGR, $11.7B calculated opportunity.
- HS 284420: +28.4% average CAGR, $1.7B calculated opportunity.
- HS 284390: +28.3% average CAGR, $1.7B calculated opportunity.
- HS 293359: +28.1% average CAGR, $19.8B calculated opportunity.

## Diversification opportunities

- HS 300490: 22 buyer markets, $116.5B calculated opportunity.
- HS 300215: 16 buyer markets, $67.1B calculated opportunity.
- HS 300439: 8 buyer markets, $15.9B calculated opportunity.
- HS 382499: 7 buyer markets, $16.1B calculated opportunity.
- HS 300212: 6 buyer markets, $15.9B calculated opportunity.
- HS 300220: 5 buyer markets, $20.8B calculated opportunity.
- HS 382600: 5 buyer markets, $11.7B calculated opportunity.
- HS 293719: 4 buyer markets, $33.8B calculated opportunity.
- HS 300214: 4 buyer markets, $30.9B calculated opportunity.
- HS 293399: 3 buyer markets, $16.8B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.